AndreaBozzo/ceres-open-data-index huggingface dataset:
NNDSS - TABLE 1BB. Q fever, Total to Q fever, Chronic

NNDSS - TABLE 1BB. Q fever, Total to Q fever, Chronic - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Patent AT-E399614-T1: [Translated] Welding device and procedure for connecting a first sheet to a second partially concentrated sheet metal using the pressure reductions between the two sheets and using the first tin relative to locate it by means of pres

The present invention relates to an apparatus and a method which may be used for welding a first panel (24) to a second panel (22), the first panel (24) having an inboard side (34) partially contacting the second panel (22) and an opposite outboard side (36). The apparatus has means for generating a welding beam. The apparatus has means for reducing a pressure along the inboard side (34) of the first panel (24) relative to an adjacent pressure along the outboard side (36) so as to produce inward deflection of the first panel (24) along a first portion (40) of the first panel not contacting the second panel (22) relative to a second portion (42). The apparatus further has means for locating the means for generating the welding beam based on said deflection at least one of said first portion (40) or said second portion (42).
Patent AT-E401392-T1: [Translated] SUBTYPE-MATCHED INACTIVATED WHOLE VIRUS VACCINE FOR THE TREATMENT OF PATIENTS WITH HIV INFECTION

Inactivated whole HIV of a particular subtype is used for vaccines and pharmaceutical compositions containing the vaccines. The vaccines can be used to treat individuals chronically infected with HIV, by inducing a protective cellular immune response in the individuals against the same HIV subtype used to produce the vaccine.
Compulsive checking behavior of quinpirole-sensitized rats as an animal model of Obsessive-Compulsive Disorder(OCD): form and control

Background
          A previous report showed that the open field behavior of rats sensitized to the dopamine agonist quinpirole satisfies 5 performance criteria for compulsive checking behavior. In an effort to extend the parallel between the drug-induced phenomenon and human obsessive-compulsive disorder (OCD), the present study investigated whether the checking behavior of quinpirole rats is subject to interruption, which is an attribute characteristic of OCD compulsions. For this purpose, the rat's home-cage was placed into the open field at the beginning or the middle of a 2-hr test.
        
        
          Results
          Introduction of the home-cage reduced checking behavior, as rats stayed inside the cage. After 40 min, checking resurfaced, as quinpirole rats exited the home-cage often. An unfamiliar cage had no such effects on quinpirole rats or saline controls.
        
        
          Conclusions
          Checking behavior induced by quinpirole is not irrepressible but can be suspended. Results strengthen the quinpirole preparation as an animal model of OCD compulsive checking.
MicroRNA-Mediated Krüppel-Like Factor 4 upregulation Induces Alternatively Activated Macrophage-Associated Markers and Chemokines Transcription in 4,4’-Methylene Diphenyl Diisocyanate Exposed Macrophages

Occupational exposure to 4,4’-methylene diphenyl diisocyanate (MDI), the most widely used monomeric diisocyanate (dNCO), is associated with occupational asthma (OA) development. Recruitment of immune cells to the lung microenvironment via secreted chemokines by alveolar macrophages may play a role during asthma pathogenesis. Our prior study identified that alternatively activated (M2) macrophage-associated markers and chemokines were induced by MDI/MDI-Glutathione (GSH)-mediated Krüppel-Like Factor 4 (KLF4) upregulation in macrophages and induced chemotaxis abilities to naïve T-cells and eosinophils; however, the underlying molecular mechanism(s) by which MDI upregulated KLF4 expression is unclear. Previously, we identified that two microRNAs (miRs) including hsa-miR-206-3p and hsa-miR-381-3p were significantly downregulated in MDI-GSH-exposed THP-1 macrophages. In silico analysis revealed that one hsa-miR-206-3p and two hsa-miR-381-3p predicted binding sites exist on the 3’ untranslated region (UTR) of KLF4 transcripts. We hypothesize that MDI/MDI-GSH exposure induces M2 macrophage-associated markers and chemokines through hsa-miR-206-3p/hsa-miR-381-3p mediated KLF4 upregulation in macrophages. The first aim of this study was to examine whether hsa-miR-206-3p/hsa-miR-381-3p regulates KLF4 expression in THP-1 macrophages through a posttranscriptional regulation mechanism. Our second aim was to determine whether hsa-miR-206-3p/hsa-miR-381-3p participates in KLF4-regulated M2 macrophage-associated markers and chemokines after MDI-exposure. After identifying the role of endogenous hsa-miR-206-3p/hsa-miR-381-3p in regulation of KLF4 transcription factor after MDI-exposure, we investigated the role of hsa-miR-206-3p/hsa-miR-381-3p in regulation of M2 macrophage-associated markers and chemokines’ expressions in relation to the exposure to MDI.
Compound 527144: 1-p-Menthen-9-yl acetate

Chemical compound data from PubChem database. IUPAC Name: 2-(4-methylcyclohex-3-en-1-yl)propyl acetate. Molecular Formula: C12H20O2. Molecular Weight: 196.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2015 Mental Health Client-Level Data Report (MH-CLD)

This report presents results from the Mental Health Client-Level Data (MH-CLD) and Mental Health Treatment Episode Data Set (MH-TEDS) for individuals receiving mental health treatment services in 2015, as well as selected data collection trends for such individuals from 2012 to 2015. The report provides information on mental health diagnoses, mental health treatment services, and demographic and substance use characteristics of individuals in mental health treatment in facilities that reported to individual state administrative data systems. One chapter is also devoted to characteristics of admissions to and discharges from mental health treatment, which can feature the same individual on multiple occasions.
Astroglial expression of the P-glycoprotein is controlled by intracellular CNTF

Background
          The P-glycoprotein (P-gp), an ATP binding cassette transmembrane transporter, is expressed by astrocytes in the adult brain, and is positively modulated during astrogliosis. In a search for factors involved in this modulation, P-gp overexpression was studied in long-term in vitro astroglial cultures.
        
        
          Results
          Surprisingly, most factors that are known to induce astroglial activation in astroglial cultures failed to increase P-gp expression. The only effective proteins were IFNγ and those belonging to the IL-6 family of cytokines (IL-6, LIF, CT-1 and CNTF). As well as P-gp expression, the IL-6 type cytokines - but not IFNγ - stimulated the expression of endogenous CNTF in astrocytes. In order to see whether an increased intracellular level of CNTF was necessary for induction of P-gp overexpression by IL-6 type cytokines, by the same cytokines analysis was carried out on astrocytes obtained from CNTF knockout mice. In these conditions, IFNγ produced increased P-gp expression, but no overexpression of P-gp was observed with either IL-6, LIF or CT-1, pointing to a role of CNTF in the intracellular signalling pathway leading to P-gp overexpression. In agreement with this suggestion, application of exogenous CNTF -which is internalised with its receptor - produced an overexpression of P-gp in CNTF-deficient astrocytes.
        
        
          Conclusions
          These results reveal two different pathways regulating P-gp expression and activity in reactive astrocytes, one of which depends upon the intracellular concentration of CNTF. This regulation of P-gp may be one of the long searched for physiological roles of CNTF.
Patent AT-E400272-T1: [Translated] PIPERIDINE COMPOUNDS AS MALONYL-COA DECARBOXYLASE INHIBITORS

The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.
Georgia (GA)

This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for Georgia overall and for substate regions within Georgia. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Protecting the Rights of Qualified Individuals with Disabilities: Technical Assistance under Section 504 of the Rehabilitation Act of 1973 for State, Tribal, and Territorial Child Welfare Agencies and Courts

The purpose of this Information Memorandum (IM) is to inform state and tribal title IV-B and title IV-E agencies of a final rule issued by the United States Department of Health and Human Services (HHS) Office for Civil Rights (OCR) that implements Section 504 of the Rehabilitation Act of 1973 (Section 504). HHS’s final rule includes regulatory provisions relevant to child welfare agencies that receive Federal financial assistance from the U.S. Department of Health and Human Services. These regulatory provisions clarify how Section 504 applies in the child welfare context. This guidance focuses on the Section 504 final rule and does not cover all disability rights laws applicable to child welfare entities.

Metadata-only record linking to the original dataset. Open original dataset below.
Evaluating Coverage of Selected Domains in the National Survey on Drug Use and Health

This report evaluates NSDUH\'s coverage of several demographic, socioeconomic, and geographic domains or subpopulations that are of interest to data users. It is intended to be an informative summary of NSDUH coverage with respect to other sources of data. In most cases, the data source that is used for comparison is a primary source of information on that domain or another flagship survey of HHS.
Quetiapine fumarate

Quetiapine Fumarate is a generic atypical antipsychotic medication used to treat conditions like schizophrenia and bipolar disorder. It comes as oral tablets in strengths of 25mg, 50mg, 100mg, 150mg, 200mg, 300mg, and 400mg, manufactured by Aurobindo Pharma Ltd. This information was generated using AI and is provided for informational and research purposes only.
Compound 526032: Silane, [[(16alpha,17beta)-2-methoxyestra-1,3,5(10)-triene-3,16,17-triyl]tris(oxy)]tris*trimethyl-

Chemical compound data from PubChem database. IUPAC Name: [2-methoxy-13-methyl-3,16-bis(trimethylsilyloxy)-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]oxy-trimethylsilane. Molecular Formula: C28H50O4Si3. Molecular Weight: 534.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2014 CMHS Uniform Reporting System (URS) Table for South Dakota

2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for South Dakota. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 527440: 3-Mercapto-2-methylpropanal

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-3-sulfanylpropanal. Molecular Formula: C4H8OS. Molecular Weight: 104.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525859: N,N-Dimethyl-2-phenyl-N'-benzyl-acetamidine

Chemical compound data from PubChem database. IUPAC Name: N'-benzyl-N,N-dimethyl-2-phenylethanimidamide. Molecular Formula: C17H20N2. Molecular Weight: 252.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400932-T1: [Translated] METHOD FOR CONTROLLING THE TRANSMISSION OF MESSAGE SIGNALS

The present invention concerns a method for controlling the transfer of signals representatives of a group of data in a wireless telecommunication network comprising a first telecommunication device linked through plural second telecommunication devices through the wireless network, the first telecommunication device comprising at least two antennas, at least one of the second telecommunication devices comprising at least two antennas. The first telecommunication device calculates at least two information, each information being representative of the achievable link conditions between the first telecommunication device and one second telecommunication device, determines which second telecommunication device is involved in the transfer of the group of data through the link according to the determined information and determines at least a weighting vector to be used for the transfer of the group of data, the elements of the weighting vector weighting the signals representatives of the group of data transferred through at least two antennas.
Compound 526774: 9-Hydroxy-stearic acid, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 9-[tert-butyl(dimethyl)silyl]oxyoctadecanoate. Molecular Formula: C25H52O3Si. Molecular Weight: 428.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528529: Naphthalene, decahydro-, 1,1'-bis

Chemical compound data from PubChem database. IUPAC Name: 1-(1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-1-yl)-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalene. Molecular Formula: C20H34. Molecular Weight: 274.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2012-2014 Substate Estimates of Substance Use and Mental Illness

Substate estimates for 25 measures of substance use and mental illness based on the combined 2012, 2013, and 2014 National Surveys on Drug Use and Health (NSDUHs) are provided. NSDUH is an ongoing survey of the civilian, noninstitutionalized population of the United States aged 12 years or older. Estimates presented here are based on a small area estimation (SAE) methodology in which substate-level NSDUH data are combined with county and census block group/tract-level data from the state.
QHP Landscape Instructions PY2025 Medical SHOP

The Medical SHOP Market file of the QHP Landscape Files contains information on certified medical plans offered through an Exchange to employers in the Small Business Health Options Program (SHOP) market. These plans are also known as Qualified Health Plans (QHPs). The file reports plans offered by county for states in the Federally-facilitated Exchanges including states performing plan management functions, and State Based Exchanges using the federal platform for eligibility and enrollment.
SFHSS Demographics Report

Annually, the San Francisco Health Service System (SFHSS) publishes a demographic report of its membership.  SFHSS administers comprehensive health benefits for employees and retirees from the City and County of San Francisco (CCSF), San Francisco Unified School District (SFUSD), City College of San Francisco (SFCCD), and the Superior Court of San Francisco (CRT), as well as their eligible dependents.
Supporting Evidence-Based Home Visitation Programs to Prevent Child Maltreatment (EBHV)

In 2008, the Children’s Bureau (CB) within the Administration for Children and Families (ACF) at the U.S. Department of Health and Human Services funded 17 cooperative agreements (subcontractors) to support the development of infrastructure needed for the high quality implementation of grantee-selected evidence-based home visitation programs to prevent child maltreatment. CB/ACF funded Mathematica Policy Research and Chapin Hall at the University of Chicago to design and conduct a participatory and utilization-focused cross-site evaluation of the subcontractors’ programs. The primary purpose of the cross-site evaluation was to augment the existing evidence base by identifying successful strategies for adopting, implementing, and sustaining high quality home visiting programs to prevent child maltreatment. The national cross-site evaluation included four domains: (1) systems change and infrastructure building, (2) fidelity to evidence-based home visiting models, (3) cost analysis, and (4) a process study. The project will archive data used to assess the fidelity to five evidence-based home visiting models, including data on staff and participant characteristics, service data, and the Working Alliance Inventory, an instrument design to assess home visitor-participant relationships. Data were submitted by 48 implementing agencies from 16 of the EBHV subcontractors. These data describe service delivery between October 1, 2009 and June 30, 2012.  Researchers who are interested in this Restricted dataset should email NDACAN to request the dataset codebooks before they decide to apply for this dataset.

Investigators: Boller, K., Daro, D. A., Del Grasso, P., Cole, R., Paulsell, D., Hart, B., Coffee-Borden, B., Strong, D., & Hargreaves, M.
Compound 528196: Benzeneacetic acid, 2'-hydroxy, DTBS

Chemical compound data from PubChem database. IUPAC Name: 2,2-ditert-butyl-5H-1,3,2-benzodioxasilepin-4-one. Molecular Formula: C16H24O3Si. Molecular Weight: 292.44. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
U.S. State and Territorial Public Mask Mandates From April 8, 2020 through August 15, 2021 by State by Day

State and territorial executive orders, administrative orders, resolutions, and proclamations are collected from government websites and cataloged and coded using Microsoft Excel by one coder with one or more additional coders conducting quality assurance.

Data were collected to determine when members of the public in states and territories were subject to state and territorial executive orders, administrative orders, resolutions, and proclamations for COVID-19 that require them to wear masks in public. “Members of the public” are defined as individuals operating in a personal capacity. “In public” is defined to mean either (1) anywhere outside the home or (2) both in retail businesses and in restaurants/food establishments. Data consists exclusively of state and territorial orders.

These data are derived from publicly available state and territorial executive orders, administrative orders, resolutions, and proclamations (“orders”) for COVID-19 that expressly require individuals to wear masks in public found by the CDC, COVID-19 Community Intervention & Critical Populations Task Force, Monitoring & Evaluation Team, Mitigation Policy Analysis Unit, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program, and Max Gakh, Assistant Professor, School of Public Health, University of Nevada, Las Vegas from April 8, 2020 through  August 15, 2021. These data will be updated as new orders are collected. Any orders not available through publicly accessible websites are not included in these data. Only official copies of the documents or, where official copies were unavailable, official press releases from government websites describing requirements were coded; news media reports on restrictions were excluded. Recommendations not included in an order are not included in these data. Effective and expiration dates were coded using only the dates provided; no distinction was made based on the specific time of the day the order became effective or expired. These data do not include data on counties that have opted out of their state mask mandate pursuant to state law. These data do not necessarily represent an official position of the Centers for Disease Control and Prevention.